| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
SEW2871 (SEW-2871) is a S1P1 agonist (sphingosine-1-phosphate type 1 receptor agonist) with EC50 of 13.8 nM. SEW2871 enhances cognitive performance in rats modelled by Alzheimer's disease. SEW2871 increases the survival time of mice receiving heterotopic heart allografts. When it comes to the lysis of K562 tumor cells and dendritic cells mediated by natural killer cells, SEW2871 reverses the inhibitory effect of S1P, but not when it comes to cytokine release. SEW2871 increases the survival time of mice receiving heterotopic heart allografts. Diabetes, Alzheimer's, liver fibrosis, and inflammatory reactions are among the conditions for which it might be used.
| Targets |
S1PR1 ( EC50 = 13.8 nM )
|
|---|---|
| ln Vitro |
SEW2871 shows enhanced migration effects by upregulating smooth muscle α-actin, procollagen αI and αIII, and total collagen content in LX-2 cells, a human hepatic stellate cell line [2].
|
| ln Vivo |
SEW2871 (20 mg/kg, gavage, once daily for 2 weeks) improves established experimental ductitis in IL-10–/– mice [3]. SEW2871 (0.5 mg/kg IP once daily) SEW2871 (0-0.3 mg/kg IV for 2 weeks) inhibits amyloid beta (Aβ1-42) in a trajectory model of Alzheimer's disease Induced spatial impairment memory and hippocampal neuron loss [2]. ) attenuates LPS-induced acute stress-induced lung injury in C57Bl/6 electrodes by producing the required alveolar and vascular septal protection [2]. SEW2871 reduces CD4+ T cell respiration inside the electrode and effectively protects cardiovascular short circuit animal models: IL-10–/– (interleukin (IL)-10 gene deficiency) mice, mouse model of Crohn’s disease (CD) [3] Dosage: 20 mg/kg Administration method: gavage. , once daily for 2 weeks Results: Colitis ameliorated in IL-10–/– mice, associated with reduced serum amyloid A concentration, reduced colonic MPO concentration, peripheral CD4+CD45+ T cell depletion, and T cell homing to colon LP. Inhibits typical cytokine and p-STAT-3 expression of type 1 helper T (Th1) and Th17 cells, and significantly reduces TNF-α, IFN-γ, IL-1β, and IL-17A mRNA levels.
|
| Animal Protocol |
IL-10–/– (interleukin (IL)-10 gene-deficient) mice, a murine model of Crohn's disease (CD)
20 mg/kg Gavage, once daily for 2 weeks |
| References |
|
| Molecular Formula |
C20H10F6N2OS
|
|---|---|
| Molecular Weight |
440.3616
|
| Exact Mass |
440.04
|
| Elemental Analysis |
C, 54.55; H, 2.29; F, 25.89; N, 6.36; O, 3.63; S, 7.28
|
| CAS # |
256414-75-2
|
| Related CAS # |
256414-75-2
|
| Appearance |
Solid powder
|
| SMILES |
C1=CC=C(C=C1)C2=C(SC(=C2)C3=NC(=NO3)C4=CC(=CC=C4)C(F)(F)F)C(F)(F)F
|
| InChi Key |
OYMNPJXKQVTQTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H10F6N2OS/c21-19(22,23)13-8-4-7-12(9-13)17-27-18(29-28-17)15-10-14(11-5-2-1-3-6-11)16(30-15)20(24,25)26/h1-10H
|
| Chemical Name |
5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
|
| Synonyms |
SEW2871; SEW2871; SEW2871
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~25 mg/mL (~56.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2709 mL | 11.3543 mL | 22.7087 mL | |
| 5 mM | 0.4542 mL | 2.2709 mL | 4.5417 mL | |
| 10 mM | 0.2271 mL | 1.1354 mL | 2.2709 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
